Abstract
In almost every epidemiological analysis so far performed a strong correlation always emerges between degree of hyperglycemia and risk of both micro- and macrovascular complications. However, whereas lowering plasma glucose levels by intensive treatment has proven to reduce the risk of development of retinopathy, nephropathy and neuropathy, the effect on macrovascular complications has remained quite doubtful. Multiple factors may have concurred to this negative findings including long duration of diabetes, poor pre-existing glycaemic control, potentially inadequate anti-diabetes drugs. Another potential explanation is that, given the high cardiovascular risk of the diabetic patients they were already aggressively treated as far as their cardiovascular risk factors are concerned. The annual mortality in these diabetic cohorts was, indeed, incredibly close to that of the non-diabetic population. These considerations along with the results of multiintervention studies, such as the Steno-2, supports the need for multifactorial intensive needs, definitely including glucose and lipid lowering.
Keywords: Type 2 diabetes, glycemic control, Intervention trials, cardiovascular disease, LDL-cholesterol
Current Vascular Pharmacology
Title:Glucose and LDL Lowering: The Need for Intensive Therapy
Volume: 10 Issue: 6
Author(s): Stefano Del Prato
Affiliation:
Keywords: Type 2 diabetes, glycemic control, Intervention trials, cardiovascular disease, LDL-cholesterol
Abstract: In almost every epidemiological analysis so far performed a strong correlation always emerges between degree of hyperglycemia and risk of both micro- and macrovascular complications. However, whereas lowering plasma glucose levels by intensive treatment has proven to reduce the risk of development of retinopathy, nephropathy and neuropathy, the effect on macrovascular complications has remained quite doubtful. Multiple factors may have concurred to this negative findings including long duration of diabetes, poor pre-existing glycaemic control, potentially inadequate anti-diabetes drugs. Another potential explanation is that, given the high cardiovascular risk of the diabetic patients they were already aggressively treated as far as their cardiovascular risk factors are concerned. The annual mortality in these diabetic cohorts was, indeed, incredibly close to that of the non-diabetic population. These considerations along with the results of multiintervention studies, such as the Steno-2, supports the need for multifactorial intensive needs, definitely including glucose and lipid lowering.
Export Options
About this article
Cite this article as:
Del Prato Stefano, Glucose and LDL Lowering: The Need for Intensive Therapy, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520792
DOI https://dx.doi.org/10.2174/157016112803520792 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Research on Opioid Receptor Function
Current Drug Targets The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology Eidtorial from Editor-in-Chief : [ Keeping up with Advances in Cardiovascular and Hematological Medicine in 2012 ]
Cardiovascular & Hematological Agents in Medicinal Chemistry State of the Art in Medical and Surgical Management of Pneumothorax
Current Respiratory Medicine Reviews Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Hyperglycemia and Perioperative Glucose Management
Current Pharmaceutical Design Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Geriatric Psychopharmacology in Acute Settings
Current Psychopharmacology PDE-5 Inhibitors: Clinical Points
Current Drug Targets The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Medicinal Plants with Multiple Effects on Cardiovascular Diseases: A Systematic Review
Current Pharmaceutical Design Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Current Medicinal Chemistry Comparison of the Mean Minimum Dose of Bolus Oxytocin for Proper Uterine Contraction during Cesarean Section
Current Clinical Pharmacology Neurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Current Cardiology Reviews Nitric Oxide-NASIDS Donor Prodrugs as Hybrid Safe Anti-inflammatory Agents
Current Topics in Medicinal Chemistry Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension
Current Vascular Pharmacology Protective Effect of Dietary Potassium against Cardiovascular Damage in Salt-Sensitive Hypertension: Possible Role of its Antioxidant Action
Current Vascular Pharmacology Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design